Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Status:
Completed
Trial end date:
2020-12-02
Target enrollment:
Participant gender:
Summary
In this study, the researchers want to learn more about Vigil and durvalumab in advanced
women's cancers: 1) how much of Vigil in combination with durvalumab (MEDI4736) can be given
with an acceptable level of side effects, 2) the effects of Vigil and durvalumab in
combination (good and bad), 3) if Vigil will cause changes in cancer cells that may help
durvalumab attack the cancer, and 4) whether or not Vigil and durvalumab will slow your
cancer or stop your cancer from getting worse.
Combining Vigil with durvalumab will allow the former to induce (or increase) the
infiltration of activated T cells into tumors, and in addition, to enhance PD-L1 (programmed
cell death ligand 1) expression. Consequently, the response rate of historically low or
un-responsive cancer will be increased with the combination of Vigil and anti PD-L1.